What We're Reading: Page 324
Industry reads hand-picked by our editors
Oct 24, 2016
-
The Economist
The trials of Juno
-
Reuters
Sanders urges Californians to approve drug price ballot measure
-
The Wall Street Journal
National Cancer Institute says researchers didn't quickly tell FDA after two deaths in a lymphoma study
Oct 21, 2016
Oct 20, 2016
-
The Wall Street Journal
Tramadol: The opioid crisis for the rest of the world
-
MIT Technology Review
On patrol with America's top bioterror cop
-
Buzzfeed
Second case emerges of someone on daily PrEP getting HIV
-
Bloomberg
Actelion using combination strategy to attack multiple sclerosis
Oct 19, 2016
-
Xconomy
After 'hubris' and its HCV collapse, can Vertex avoid same mistakes?
-
MIT Technology Review
Gene therapy in U.S. is on track for approval as early as next year
-
BloombergGadfly
Biotech shouldn't sweat the election so much
Oct 18, 2016
-
EP Vantage
M&A gives signs of reverting to the mean
-
Bloomberg
Bayer's euphoria around new cancer medicine meets skepticism
-
Healthcare Dive
Omnicare to pay $28M over alleged kickbacks from Abbott
-
Boston Globe
Veritas Genetics draws $30 million in funding
Oct 17, 2016
-
MIT Technology Review
Can CRISPR Save Ben Dupree?
-
Bloomberg
Gels to repair hearing loss? Drugmakers try new ear treatments
-
The Street
Celgene Crohn's pill data unspectacular but perhaps good enough
-
Journal Sentinel
With overactive bladder, drug companies helped create $3 billion market
Previous
